|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
PLoS By Category | Recent
PLoS Articles
|
|
Anesthesiology and Pain Management - Biochemistry - Biophysics - Biotechnology - Cardiovascular Disorders - Chemical Biology - Chemistry - Computer Science - Critical Care and Emergency Medicine - Dermatology - Diabetes and Endocrinology - Ecology - Evidence-Based Healthcare - Gastroenterology and Hepatology - Geriatrics - Hematology - Immunology - Infectious Diseases - Mathematics - Mental Health - Microbiology - Molecular Biology - Nephrology - Neurological Disorders - Neuroscience - Non-Clinical Medicine - Nutrition - Obstetrics - Oncology - Ophthalmology - Otolaryngology - Pathology - Pediatrics and Child Health - Pharmacology - Physics - Physiology - Public Health and Epidemiology - Radiology and Medical Imaging - Respiratory Medicine - Rheumatology - Science Policy - Surgery - Urology - Virology - Women's Health
|
Eradication of Metastatic Renal Cell Carcinoma after Adenovirus-Encoded TNF-Related Apoptosis-Inducing Ligand (TRAIL)/CpG Immunotherapy
Published:
Wednesday, February 01, 2012
Author:
Lyse A. Norian et al.
by Lyse A. Norian, Timothy P. Kresowik, Henry M. Rosevear, Britnie R. James, Timothy R. Rosean, Andrew J. Lightfoot, Tamara A. Kucaba, Christopher Schwarz, Christine J. Weydert, Michael D. Henry, Thomas S. Griffith
Despite evidence that antitumor immunity can be protective against renal cell carcinoma (RCC), few patients respond objectively to immunotherapy and the disease is fatal once metastases develop. We asked to what extent combinatorial immunotherapy with Adenovirus-encoded murine TNF-related apoptosis-inducing ligand (Ad5mTRAIL) plus CpG oligonucleotide, given at the primary tumor site, would prove efficacious against metastatic murine RCC. To quantitate primary renal and metastatic tumor growth in mice, we developed a luciferase-expressing Renca cell line, and monitored tumor burdens via bioluminescent imaging. Orthotopic tumor challenge gave rise to aggressive primary tumors and lung metastases that were detectable by day 7. Intra-renal administration of Ad5mTRAIL+CpG on day 7 led to an influx of effector phenotype CD4 and CD8 T cells into the kidney by day 12 and regression of established primary renal tumors. Intra-renal immunotherapy also led to systemic immune responses characterized by splenomegaly, elevated serum IgG levels, increased CD4 and CD8 T cell infiltration into the lungs, and elimination of metastatic lung tumors. Tumor regression was primarily dependent upon CD8 T cells and resulted in prolonged survival of treated mice. Thus, local administration of Ad5mTRAIL+CpG at the primary tumor site can initiate CD8-dependent systemic immunity that is sufficient to cause regression of metastatic lung tumors. A similar approach may prove beneficial for patients with metastatic RCC.
More...
|
|
|
 |
|
|
|
|
|
|
|
|